Loading...
SeqLL Inc.
SQLLW•NASDAQ
Healthcare
Medical - Diagnostics & Research
$0.002
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $0.00 in Q4 2023 to $107.80M in Q3 2024. Gross profit continued to perform well, with margins at 11% in the latest quarter. Operating income reached -$6.51M in Q3 2024, holding a steady -6% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.55M. Net income rose to -$7.05M, keeping EPS at -$6.31. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan